PMID- 33348839
OWN - NLM
STAT- MEDLINE
DCOM- 20210204
LR  - 20210204
IS  - 1660-4601 (Electronic)
IS  - 1661-7827 (Print)
IS  - 1660-4601 (Linking)
VI  - 17
IP  - 24
DP  - 2020 Dec 17
TI  - Plasma Inflammatory Biomarkers Associated with Advanced Liver Fibrosis in 
      HIV-HCV-Coinfected Individuals.
LID - 10.3390/ijerph17249474 [doi]
LID - 9474
AB  - BACKGROUND: HIV and HCV coinfection leads to accelerated liver fibrosis, in which 
      microbial translocation and systemic inflammation might play important roles. 
      OBJECTIVE: This study aimed to provide an extensive profile of the plasma 
      microbial translocation and inflammation biomarkers associated with advanced 
      liver fibrosis among HIV-HCV-coinfected patients. METHODS: This cross-sectional 
      study recruited 343 HIV-HCV-coinfected patients on combination antiretroviral 
      therapy (cART) from a rural prefecture of Yunnan province in Southwest China. The 
      plasma concentrations of sCD14 and 27 cytokines and chemokines were assayed and 
      compared against advanced or mild levels of liver fibrosis. RESULTS: Of the 343 
      HIV-HCV-coinfected patients, 188 (54.8%) had severe or advanced liver fibrosis 
      (FIB-4 > 3.25). The patients with advanced liver fibrosis (FIB-4 > 3.25 vs. FIB-4 
      </= 3.25) had higher plasma levels of interleukin (IL)-1beta, IL-6, IL-7, IL-9, IL-12, 
      IL-15, IL-17, granulocyte macrophage colony stimulating factor (GM-CSF), 
      Interferon-gamma (IFN-gamma), tumor necrosis factor (TNF-alpha), IL-4, IL-10, IL-13, 
      fibroblast growth factor 2 (FGF-basic), and Monocyte chemoattractant protein-1 
      (MCP-1). Multivariable logistic regression models showed that advanced liver 
      fibrosis was associated with an increased plasma level of IL-1beta, IL-6, IL-7, 
      IL-12, IL-17, GM-CSF, IFN-gamma, IL-4, IL-10, MCP-1, Eotaxin, and FGF-basic, with 
      FGF-basic continuing to be positively and significantly associated with advanced 
      liver fibrosis, after Bonferroni correction for multiple comparisons (adjusted 
      odds ratio (aOR) = 1.92; 95%CI: 1.32-2.81; p = 0.001). Plasma sCD14 was also 
      significantly associated with advanced liver fibrosis (aOR = 1.13; 95%CI: 
      1.01-1.30; p = 0.049). CONCLUSIONS: HIV-HCV-coinfected patients are living with a 
      high prevalence of advanced liver fibrosis which coexists with a mixture of 
      elevated plasma inflammation and microbial translocation biomarkers. The 
      significant associations of advanced liver fibrosis with FGF-basic and sCD14 may 
      reveal pathogenic mechanisms and potential clinical intervention targets for 
      liver fibrosis in HCV-HIV coinfection.
FAU - Chen, Xiaochen
AU  - Chen X
AD  - Department of Epidemiology, School of Public Health and the Key Laboratory of 
      Public Health Safety of Ministry of Education, Fudan University, Shanghai 200032, 
      China.
AD  - Key Laboratory of Health Technology Assessment of Ministry of Health, Fudan 
      University, Shanghai 200032, China.
FAU - Liu, Xing
AU  - Liu X
AD  - Department of Epidemiology, School of Public Health and the Key Laboratory of 
      Public Health Safety of Ministry of Education, Fudan University, Shanghai 200032, 
      China.
FAU - Duan, Song
AU  - Duan S
AD  - Dehong Prefecture Center for Disease Control and Prevention, Mangshi 678400, 
      China.
FAU - Tang, Renhai
AU  - Tang R
AD  - Dehong Prefecture Center for Disease Control and Prevention, Mangshi 678400, 
      China.
FAU - Zhou, Sujuan
AU  - Zhou S
AD  - Department of Epidemiology, School of Public Health and the Key Laboratory of 
      Public Health Safety of Ministry of Education, Fudan University, Shanghai 200032, 
      China.
FAU - Ye, Runhua
AU  - Ye R
AD  - Dehong Prefecture Center for Disease Control and Prevention, Mangshi 678400, 
      China.
FAU - Yang, Yuecheng
AU  - Yang Y
AD  - Dehong Prefecture Center for Disease Control and Prevention, Mangshi 678400, 
      China.
FAU - Wang, Jibao
AU  - Wang J
AD  - Dehong Prefecture Center for Disease Control and Prevention, Mangshi 678400, 
      China.
FAU - Yao, Shitang
AU  - Yao S
AD  - Dehong Prefecture Center for Disease Control and Prevention, Mangshi 678400, 
      China.
FAU - He, Na
AU  - He N
AD  - Department of Epidemiology, School of Public Health and the Key Laboratory of 
      Public Health Safety of Ministry of Education, Fudan University, Shanghai 200032, 
      China.
AD  - Key Laboratory of Health Technology Assessment of Ministry of Health, Fudan 
      University, Shanghai 200032, China.
LA  - eng
PT  - Journal Article
PT  - Research Support, Non-U.S. Gov't
DEP - 20201217
PL  - Switzerland
TA  - Int J Environ Res Public Health
JT  - International journal of environmental research and public health
JID - 101238455
RN  - 0 (Biomarkers)
RN  - 0 (Pharmaceutical Preparations)
SB  - IM
MH  - *Biomarkers/blood
MH  - China
MH  - *Coinfection/blood/diagnosis
MH  - Cross-Sectional Studies
MH  - Female
MH  - *HIV Infections/complications
MH  - *Hepatitis C/blood/complications/diagnosis
MH  - Humans
MH  - Liver Cirrhosis/blood/complications/diagnosis
MH  - Male
MH  - *Pharmaceutical Preparations
MH  - Plasma/chemistry
PMC - PMC7766690
OTO - NOTNLM
OT  - HCV
OT  - HIV
OT  - inflammation
OT  - liver fibrosis
OT  - microbial translocation
COIS- The authors report no conflict of interest in this work.
EDAT- 2020/12/23 06:00
MHDA- 2021/02/05 06:00
PMCR- 2020/12/01
CRDT- 2020/12/22 01:04
PHST- 2020/10/27 00:00 [received]
PHST- 2020/11/25 00:00 [revised]
PHST- 2020/12/08 00:00 [accepted]
PHST- 2020/12/22 01:04 [entrez]
PHST- 2020/12/23 06:00 [pubmed]
PHST- 2021/02/05 06:00 [medline]
PHST- 2020/12/01 00:00 [pmc-release]
AID - ijerph17249474 [pii]
AID - ijerph-17-09474 [pii]
AID - 10.3390/ijerph17249474 [doi]
PST - epublish
SO  - Int J Environ Res Public Health. 2020 Dec 17;17(24):9474. doi: 
      10.3390/ijerph17249474.